

NHS National Institute for Health Research

Manchester **Academic Health Science Centre**



Infliximab is Associated with an Increased Risk of Serious Infection in Patients with Psoriasis

Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Zenas ZN Yiu*⁺, Catherine H Smith, Darren M Ashcroft⁺, Mark Lunt, Shernaz Walton, Ruth Murphy, Nick J Reynolds, Anthony D Ormerod, Christopher EM Griffiths*, Richard B Warren*, BADBIR Study Group

British Association of Dermatologists Biologic Interventions Register, The University of Manchester, Manchester Science Park, Manchester, United Kingdom, M15 6SZ *Dermatology Centre and ⁺Centre for Pharmacoepidemiology and Drug Safety, The University of Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom M13 9PT

SUMMARY

Infliximab is associated with a higher risk of serious infection when compared to non-biologic systemic therapies in patients with psoriasis.

Patients with severe psoriasis who fulfill the criteria for the prescription of infliximab should be counselled for the associated risk of serious infection.

BACKGROUND


- **1** Adverse events (AE) can lead to discontinuation of biologics for the treatment of psoriasis¹. Of these AEs, infection is the most common.
- **2** Randomised clinical trials are not powered to investigate AEs and have low external validity²⁻³.
- **3** Risk of serious infection in patients with psoriasis on biologics is currently not well-understood.
- **4** Infliximab is prescribed to a select group of patients in the UK (PASI \geq 20; DLQI > 18).

AIM

To determine whether infliximab is associated with a higher risk of serious infection as compared to

METHODS

British Association of Dermatologists Biologic Interventions Register (BADBIR) - prospective safety registry of patients with psoriasis established in 2007 in the UK and the Republic of Ireland⁴.



Compares a cohort on biologic therapies with a cohort on nonbiologic systemic therapies with the same disease severity entry criteria: Psoriasis Area and Severity Index (PASI)≥10 and **Dermatology Life Quality Index (DLQI)>10**

Data collected 6 monthly for first 3 years, annually thereafter

Inclusion criteria

• Biologic-naive

Serious infection defined by association with:



A priori chosen co-variates

Demographics: age, gender, body mass index, waist circumference

Lifestyle factors and comorbidities: alcohol intake, smoking status, diabetes, chronic obstructive pulmonary disease (COPD), asthma, number of comorbidities

Disease severity and treatment: PASI, presence of inflammatory arthritis, concomitant immuno-suppressants for psoriasis (e.g. methotrexate) adjusted for as a time-varying covariate



Crude incidence rates calculated for infliximab (1st line / all lines of therapy); non-biologic systemic cohort.

Potential confounding from co-variates controlled for using inverse probability treatment weighting (IPTW) by propensity score generated from a multinomial logistic regression model.

Balance between cohorts after weighting assessed using expected bias from a logistic regression model estimating effects of the co-variates on the outcome.

non-biologic systemic therapies for psoriasis

- Data lock October 2016
 - Intra-venous anti-microbial
- Chronic plaque psoriasis
- Follow-up data available
- Hospitalisation and/or;
- therapy and/or; • Death


Cox proportional hazards model for hazard ratio (HR) to 1st serious infection; missing data treated with multiple imputation (20 cycles)

DISCUSSION

- **1** Crude incidence rates of serious infections for infliximab are higher than reported figures.
- 2 Adjusted results similar to PSOLAR⁵ (US based psoriasis registry) [HR 2.51 mixed prevalent/incident population; HR 1.78 incident population] when compared to acitretin/phototherapy; and BIOBADADERM⁶ (Spanish psoriasis registry)[HR 2.52] when compared to methotrexate

Strengths and weaknesses of the study

- ✓ Real-world data
- ✓ Detailed data capture
- ✓ Involvement of 153 UK and ROI centres
- ✓ Fully industry independent data analysis



Median (IQR) follow-up duration Non-biologic 1.5 (1.8) years; Infliximab (all) 1.5 (2.5) years

Expected percentage bias in relative effect for infliximab (all-lines)

Figure 1: Number of patients and median follow-up in each cohort

Treatment	Total Person- time	Infections (n=105)	Rate (/1000 person- years); 95% confidence interval (CI)
Non-biologics	6419.2	91	14.2 (11.5,17.4)
Infliximab (1st line)	238.9	14	58.6 (34.7,99.0)
Infliximab (all)	935.2	45	47.8 (35.7,64.0)

Table 1: Total person-time, number of infections, and crude incidence rate in each cohort

Before Adjustment After Adjustment

Figure 2: Forest plot showing the reduction in expected percentage bias for the individual co-variates after IPTW propensity score weighting

Treatment	Crude HR (95% CI)	Adjusted HR (95% CI)
Infliximab (1st line)	4.19 (2.42, 7.26)	1.37 (0.50, 3.74)
Infliximab (all)	3.41 (2.38, 4.90)	1.95 (1.01, 3.75)

Table 2: Crude and adjusted effect estimates for infliximab (1st and all-lines)
 against non-biologic therapies from the Cox regression models

✗ Non-randomisation

Residual confounding

Small infliximab cohort

Limited generalisability to non-UK populations

ACKNOWLEDGEMENTS

Participants of BADBIR, principal investigators, research nurses, recruiting doctors, BADBIR office team, BADBIR biologics manager, BADBIR steering and data monitoring committees, BADBIR data analysis working group.

CEMG is an National Institute for Health Research (NIHR) Senior Investigator. ZZNY is funded by a NIHR Doctoral Research Fellowship (Ref no: DRF-2015-08-089). This is a summary of independent research funded by the NIHR Doctoral Research Fellowship. The views expressed are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health.

1 Warren RB et al. (2015) J Invest Dermatol 135:2632-40. **2** Garcia-Doval et al. (2012) Arch Dermatol 148:463-70. **3** Yiu ZZ et al. (2016) J Invest Dermatol 136: 1584-91. 4 Burden AD et al. (2012) Br J Dermatol 166:545-54 5 Kalb RE et al. (2015) JAMA Dermatol 151:961-9 6 Davila-Seijo P et al. (2017) J Invest Dermatol 137:313-321

zenas.yiu@manchester.ac.uk

http://personalpages.manchester.ac.uk/staff/zenas.yiu

